AbCellera Biologics Inc (NASDAQ: ABCL) closed the day trading at $4.05 down -3.11% from the previous closing price of $4.18. On the day, 1271570 shares were traded.
Ratios:
For a better understanding of ABCL, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.32 and its Current Ratio is at 7.33. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On December 05, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $6.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 26 ’23 when Thermopylae Holdings Ltd. bought 153,000 shares for $6.52 per share. The transaction valued at 997,728 led to the insider holds 56,012,493 shares of the business.
Booth Andrew bought 14,500 shares of ABCL for $99,325 on May 26 ’23. The Chief Financial Officer now owns 153,000 shares after completing the transaction at $6.85 per share.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 31.18 while its Price-to-Book (P/B) ratio in mrq is 1.02.
Stock Price History:
Over the past 52 weeks, ABCL has reached a high of $8.05, while it has fallen to a 52-week low of $3.87.
Shares Statistics:
A total of 290.82M shares are outstanding, with a floating share count of 205.17M. Insiders hold about 29.92% of the company’s shares, while institutions hold 38.39% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from Alpha Blue Capital US Small-Mid analysts. The consensus estimate for the next quarter is $4.05, with high estimates of $12.03 and low estimates of $44.44.
Analysts are recommending an EPS of between $Financial Services and $Financial Services for the fiscal current year, implying an average EPS of $Healthcare.
